VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
L'Oreal S.A. vs Vertex Pharmaceuticals Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
L'Oreal S.A.
OR · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.
View VRTX analysisComparison highlights
- Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 80 / 100 for L'Oreal S.A.).
- Segment focus: L'Oreal S.A. has 4 segments (37% in Consumer Products Division); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
- Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: L'Oreal S.A. has 7 moat types across 3 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.
Primary market context
L'Oreal S.A.
Consumer Products Division
Mass-market beauty & personal care (skincare, haircare, makeup, hygiene)
Global
Consumers via mass retail, drugstores, supermarkets, and e-commerce
Brand owner / marketer / manufacturer
37%
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
U.S., Europe, Australia, Canada
Patients (via specialty pharmacies/payers); CF care centers
Drug developer/manufacturer
99.9%
Side-by-side metrics
Moat coverage
Shared moat types
L'Oreal S.A. strengths
Vertex Pharmaceuticals Incorporated strengths
Segment mix
L'Oreal S.A. segments
Full profile >Consumer Products Division
Oligopoly
L'Oreal Luxe Division
Oligopoly
Dermatological Beauty Division
Oligopoly
Professional Products Division
Oligopoly
Vertex Pharmaceuticals Incorporated segments
Full profile >Cystic Fibrosis CFTR Modulators
Quasi-Monopoly
Hemoglobinopathies Gene Therapy (CASGEVY)
Oligopoly
Acute Pain (JOURNAVX)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.